TY - JOUR
T1 - Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis
AU - van Dam, Lisette F.
AU - Dronkers, Charlotte E.A.
AU - Gautam, Gargi
AU - Eckerbom, Åsa
AU - Ghanima, Waleed
AU - Gleditsch, Jostein
AU - von Heijne, Anders
AU - Hofstee, Herman M.A.
AU - Hovens, Marcel M.C.
AU - Huisman, Menno V.
AU - Kolman, Stan
AU - Mairuhu, Albert T.A.
AU - Nijkeuter, Mathilde
AU - van de Ree, Marcel A.
AU - van Rooden, Cornelis J.
AU - Westerbeek, Robin E.
AU - Westerink, Jan
AU - Westerlund, Eli
AU - Kroft, Lucia J.M.
AU - Klok, Frederikus A.
N1 - Publisher Copyright:
© 2020 by The American Society of Hematology.
Copyright:
This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine
PY - 2020/4/16
Y1 - 2020/4/16
N2 - The diagnosis of recurrent ipsilateral deep vein thrombosis (DVT) is challenging, because persistent intravascular abnormalities after previous DVT often hinder a diagnosis by compression ultrasonography. Magnetic resonance direct thrombus imaging (MRDTI), a technique without intravenous contrast and with a 10-minute acquisition time, has been shown to accurately distinguish acute recurrent DVT from chronic thrombotic remains. We have evaluated the safety of MRDTI as the sole test for excluding recurrent ipsilateral DVT. The Theia Study was a prospective, international, multicenter, diagnostic management study involving patients with clinically suspected acute recurrent ipsilateral DVT. Treatment of the patients was managed according to the result of the MRDTI, performed within 24 hours of study inclusion. The primary outcome was the 3-month incidence of venous thromboembolism (VTE) after a MRDTI negative for DVT. The secondary outcome was the interobserver agreement on the MRDTI readings. An independent committee adjudicated all end points. Three hundred five patients were included. The baseline prevalence of recurrent DVT was 38%; superficial thrombophlebitis was diagnosed in 4.6%. The primary outcome occurred in 2 of 119 (1.7%; 95% confidence interval [CI], 0.20-5.9) patients with MRDTI negative for DVT and thrombophlebitis, who were not treated with any anticoagulant during follow-up; neither of these recurrences was fatal. The incidence of recurrent VTE in all patients with MRDTI negative for DVT was 1.1% (95% CI, 0.13%-3.8%). The agreement between initial local and post hoc central reading of the MRDTI images was excellent (κ statistic, 0.91). The incidence of VTE recurrence after negative MRDTI was low, and MRDTI proved to be a feasible and reproducible diagnostic test. This trial was registered at www.clinicaltrials.gov as #NCT02262052.
AB - The diagnosis of recurrent ipsilateral deep vein thrombosis (DVT) is challenging, because persistent intravascular abnormalities after previous DVT often hinder a diagnosis by compression ultrasonography. Magnetic resonance direct thrombus imaging (MRDTI), a technique without intravenous contrast and with a 10-minute acquisition time, has been shown to accurately distinguish acute recurrent DVT from chronic thrombotic remains. We have evaluated the safety of MRDTI as the sole test for excluding recurrent ipsilateral DVT. The Theia Study was a prospective, international, multicenter, diagnostic management study involving patients with clinically suspected acute recurrent ipsilateral DVT. Treatment of the patients was managed according to the result of the MRDTI, performed within 24 hours of study inclusion. The primary outcome was the 3-month incidence of venous thromboembolism (VTE) after a MRDTI negative for DVT. The secondary outcome was the interobserver agreement on the MRDTI readings. An independent committee adjudicated all end points. Three hundred five patients were included. The baseline prevalence of recurrent DVT was 38%; superficial thrombophlebitis was diagnosed in 4.6%. The primary outcome occurred in 2 of 119 (1.7%; 95% confidence interval [CI], 0.20-5.9) patients with MRDTI negative for DVT and thrombophlebitis, who were not treated with any anticoagulant during follow-up; neither of these recurrences was fatal. The incidence of recurrent VTE in all patients with MRDTI negative for DVT was 1.1% (95% CI, 0.13%-3.8%). The agreement between initial local and post hoc central reading of the MRDTI images was excellent (κ statistic, 0.91). The incidence of VTE recurrence after negative MRDTI was low, and MRDTI proved to be a feasible and reproducible diagnostic test. This trial was registered at www.clinicaltrials.gov as #NCT02262052.
KW - Adult
KW - Aged
KW - Anticoagulants/therapeutic use
KW - Female
KW - Humans
KW - Incidence
KW - Magnetic Resonance Imaging/methods
KW - Male
KW - Middle Aged
KW - Prospective Studies
KW - Recurrence
KW - Venous Thrombosis/diagnostic imaging
UR - http://www.scopus.com/inward/record.url?scp=85093902705&partnerID=8YFLogxK
U2 - 10.1182/blood.2019004114
DO - 10.1182/blood.2019004114
M3 - Article
C2 - 32016390
AN - SCOPUS:85093902705
SN - 0006-4971
VL - 135
SP - 1377
EP - 1385
JO - Blood
JF - Blood
IS - 16
ER -